PE20020335A1 - Acetamida de benceno de alfa-acil- y alfa-heteroatomo-sustituido como activadores de la glucoquinasa - Google Patents

Acetamida de benceno de alfa-acil- y alfa-heteroatomo-sustituido como activadores de la glucoquinasa

Info

Publication number
PE20020335A1
PE20020335A1 PE2001000731A PE2001000731A PE20020335A1 PE 20020335 A1 PE20020335 A1 PE 20020335A1 PE 2001000731 A PE2001000731 A PE 2001000731A PE 2001000731 A PE2001000731 A PE 2001000731A PE 20020335 A1 PE20020335 A1 PE 20020335A1
Authority
PE
Peru
Prior art keywords
alpha
acil
heteroatome
dichloro
acetyl
Prior art date
Application number
PE2001000731A
Other languages
English (en)
Inventor
Robert Francis Kester
Ramakanth Sarabu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20020335A1 publication Critical patent/PE20020335A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

SE REFIERE A UNA AMIDA DE FORMULA I DONDE R1 Y R2 SON H, HALO, CIANO, NITRO, ALQUILO, TIO, PERFLUOROALQUILOTIO, ALQUILOSULFONILO, PERFLUOROALQUILOSULFONILO, ENTRE OTROS; R3 ES ALQUILO C2-C4, CICLOALQUILO, CICLOALQUENILO, HETEROCICLOALQUILO; R4 ES CONHR5, R6; R6 ES UN ANILLO HETEROAROMATICO DE 5-6 MIEMBROS; R1 ES ALQUILOHIDROXILO, HALOALQUILO, (CH2)NCOOR7, CO-(CH2)n-(O)-OR8; n ES 0-4; R7, R8, R9, R10, R11, R12, R13 SON H, ALQUILO; X ES O, S, SULFONILO, CARBONILO. SON COMPUESTOS PREFERIDOS 1-[CICLOPENTILOXI-(3,4-DICLORO-FENIL)-ACETIL]-3-METIL-UREA; 1-[CICLOHEXILOXI-(3,4-DICLORO-FENIL)-ACETIL]-3-METIL-UREA, 1-[(CICLOHEX-2-ENILOXI)-(3,4-DICLORO-FENIL)-ACETIL]-3-METIL-UREA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCESO PARA LA PPREPARACION. EL COMPUESTO I ES ACTIVADOR DE GLUCOQUINASA Y PUEDE SER UTIL PARA EL TRATAMIENTO DE DIABETES
PE2001000731A 2000-07-20 2001-07-19 Acetamida de benceno de alfa-acil- y alfa-heteroatomo-sustituido como activadores de la glucoquinasa PE20020335A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21987200P 2000-07-20 2000-07-20

Publications (1)

Publication Number Publication Date
PE20020335A1 true PE20020335A1 (es) 2002-04-30

Family

ID=22821104

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000731A PE20020335A1 (es) 2000-07-20 2001-07-19 Acetamida de benceno de alfa-acil- y alfa-heteroatomo-sustituido como activadores de la glucoquinasa

Country Status (21)

Country Link
US (2) US6486184B2 (es)
EP (1) EP1305301B1 (es)
JP (1) JP4138478B2 (es)
KR (1) KR100556323B1 (es)
CN (1) CN1184214C (es)
AR (1) AR032626A1 (es)
AT (1) ATE297907T1 (es)
AU (2) AU8760001A (es)
BR (1) BR0112658A (es)
CA (1) CA2416229C (es)
DE (1) DE60111534T2 (es)
DK (1) DK1305301T3 (es)
ES (1) ES2243547T3 (es)
GT (1) GT200100146A (es)
MX (1) MXPA03000365A (es)
PA (1) PA8522701A1 (es)
PE (1) PE20020335A1 (es)
PT (1) PT1305301E (es)
UY (1) UY26850A1 (es)
WO (1) WO2002008209A1 (es)
ZA (1) ZA200300173B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1336607A1 (en) * 2002-02-19 2003-08-20 Novo Nordisk A/S Amide derivatives as glucokinase activators
CN100506807C (zh) 2001-12-21 2009-07-01 诺沃挪第克公司 作为gk活化剂的酰胺衍生物
UA80427C2 (en) 2002-04-26 2007-09-25 Hoffmann La Roche Substituted phenylacetamides and their use as glucokinase activators
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
BR0314864A (pt) 2002-10-03 2005-08-02 Novartis Ag Compostos orgânicos
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
CA2539596A1 (en) 2003-09-30 2005-04-07 Kilian Waldemar Conde-Frieboes Melanocortin receptor agonists
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
WO2005066145A1 (en) 2004-01-06 2005-07-21 Novo Nordisk A/S Heteroaryl-ureas and their use as glucokinase activators
AU2005229415B2 (en) 2004-04-02 2009-05-14 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
CA2560689C (en) 2004-04-02 2011-03-01 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful in the treatment of type 2 diabetes
MXPA06012008A (es) * 2004-04-21 2007-01-25 Prosidion Ltd Compuestos de amida tri(ciclo) sustituidos.
EP1758575A1 (en) 2004-06-11 2007-03-07 Novo Nordisk A/S Counteracting drug-induced obesity using glp-1 agonists
GB0418046D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Eantioselective process
KR20080105180A (ko) * 2004-08-12 2008-12-03 프로시디온 리미티드 치환된 페닐아세트아미드 및 글루코키나제 활성화제로서의 그의 용도
EP1904466A1 (en) * 2005-07-08 2008-04-02 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
ATE547396T1 (de) 2005-07-08 2012-03-15 Novo Nordisk As Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
WO2007006814A1 (en) 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
US20090281142A1 (en) 2005-08-31 2009-11-12 Astellas Pharma Inc. Thiazole derivative
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
BRPI0617207A2 (pt) 2005-09-29 2011-07-19 Sanofi Aventis derivados de fenil-1,2,4-oxadiazolona, processos para sua preparação e seu uso como produtos farmacêuticos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
JP2009514835A (ja) * 2005-11-03 2009-04-09 プロシディオン・リミテッド トリシクロ置換型アミド
SI1951658T1 (sl) 2005-11-17 2012-11-30 Lilly Co Eli Antagonisti glukagonskega receptorja priprava interapevtska uporaba
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
CA2669874A1 (en) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
EP2091947A2 (en) 2006-12-20 2009-08-26 Takeda San Diego, Inc. Glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
JP2010515701A (ja) 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
CA2679185A1 (en) 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
TW200902489A (en) * 2007-03-07 2009-01-16 Kyorin Seiyaku Kk Glucokinase-activating substance
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US9340506B2 (en) 2007-10-08 2016-05-17 Advinus Therapeutics Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
US8501955B2 (en) 2007-10-08 2013-08-06 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal application
AR070107A1 (es) * 2008-01-15 2010-03-17 Lilly Co Eli R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
KR20100113518A (ko) 2008-01-18 2010-10-21 아스텔라스세이야쿠 가부시키가이샤 페닐아세트아미드 유도체
EP2275414B1 (en) 2008-04-28 2015-06-10 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
GEP20135783B (en) 2008-05-16 2013-03-11 Takeda California Inc Glucokinase activators
US8450494B2 (en) 2009-06-22 2013-05-28 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (GK) activators
CA2768232A1 (en) 2009-07-31 2011-02-03 Cadila Healthcare Limited Substituted benzamide derivatives as glucokinase (gk) activators
WO2011080755A1 (en) 2009-12-29 2011-07-07 Advinus Therapeutics Private Limited Fused nitrogen heterocyclic compounds, process of preparation and uses thereof
WO2011095997A1 (en) 2010-02-08 2011-08-11 Advinus Therapeutics Private Limited Benzamide compounds as glucokinase activators and their pharmaceutical application
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
AU2011231503C1 (en) 2010-03-26 2016-03-03 Novo Nordisk A/S Novel glucagon analogues
CN105176930B (zh) 2010-03-31 2021-05-04 斯克里普斯研究所 重编程细胞
EP2402327B1 (en) 2010-06-29 2018-03-07 Impetis Biosciences Ltd. Acetamide compounds as glucokinase activators, their process and medicinal applications
BR112013024076A2 (pt) 2011-03-28 2016-12-06 Novo Nordisk As análogos de glucagon
RU2610175C2 (ru) 2011-09-23 2017-02-08 Ново Нордиск А/С Новые аналоги глюкагона
MX362275B (es) 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
CN111032680A (zh) 2017-03-15 2020-04-17 诺和诺德股份有限公司 能够与黑皮质素4受体结合的双环化合物
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
CA3093025A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776917A (en) * 1972-06-05 1973-12-04 Schering Corp 2-amino-6-phenalkyl-aminopyridines and derivatives thereof
JPS5564592A (en) * 1978-11-10 1980-05-15 Teijin Ltd Thiazolo 3, 2-a pyrimidine derivative, its preparation, and drug comprising it
JPS62153273A (ja) * 1985-12-26 1987-07-08 Tokuyama Soda Co Ltd ピラゾ−ル化合物
MXPA01009814A (es) * 1999-03-29 2002-04-24 Hoffmann La Roche Activadores de la glucoquinasa.

Also Published As

Publication number Publication date
DE60111534D1 (de) 2005-07-21
US20020198200A1 (en) 2002-12-26
CA2416229A1 (en) 2002-01-31
DE60111534T2 (de) 2006-05-11
WO2002008209A1 (en) 2002-01-31
UY26850A1 (es) 2002-01-31
EP1305301B1 (en) 2005-06-15
ZA200300173B (en) 2004-04-07
KR100556323B1 (ko) 2006-03-03
ATE297907T1 (de) 2005-07-15
PA8522701A1 (es) 2002-10-24
AU2001287600B2 (en) 2006-07-13
KR20030016419A (ko) 2003-02-26
AU8760001A (en) 2002-02-05
JP2004504388A (ja) 2004-02-12
US20020042512A1 (en) 2002-04-11
DK1305301T3 (da) 2005-10-17
CN1443177A (zh) 2003-09-17
CN1184214C (zh) 2005-01-12
PT1305301E (pt) 2005-09-30
ES2243547T3 (es) 2005-12-01
JP4138478B2 (ja) 2008-08-27
EP1305301A1 (en) 2003-05-02
AR032626A1 (es) 2003-11-19
US6608218B2 (en) 2003-08-19
GT200100146A (es) 2002-07-04
MXPA03000365A (es) 2003-05-27
US6486184B2 (en) 2002-11-26
CA2416229C (en) 2007-09-18
BR0112658A (pt) 2003-06-24

Similar Documents

Publication Publication Date Title
PE20020335A1 (es) Acetamida de benceno de alfa-acil- y alfa-heteroatomo-sustituido como activadores de la glucoquinasa
PE20011310A1 (es) Alquinil fenil amidas heteroaromaticas como activadores de la glucokinasa
PE20020056A1 (es) Fenil amidas para-aril o heteroaril sustituidas como activadores de la glucoquinasa
PE20001584A1 (es) Activadores de la glucoquinasa
PE20011022A1 (es) Compuestos trans olefinicos activadores glucoquinasa
PE20020771A1 (es) Pirrolidina fusionada con ciclopropilo como inhibidores de dipeptidil peptidas iv
PE20020504A1 (es) N-acilsulfonamidas promotoras de apoptosis
PE20051048A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasa
ES2184482T3 (es) Benzazoles, derivados del venzoxazol, el benzotiazol y el bencimidazol.
PE20020049A1 (es) Fenilamidas para amina sustituidas como activadores de glucoquinasa
PE20040071A1 (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
UY27357A1 (es) Nuevos agentes antidiabéticos .
ATE163012T1 (de) N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel
PE20011066A1 (es) PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
PE20020509A1 (es) Aza y poliaza-naftalenil carboxamidas utiles como inhibidores de la integrasa del vih
ES2174757B1 (es) Empleo de derivados de firazolinas en la elaboracion de un medicamentopara la prevencion y/o el tratamiento de enfermedades proliferativas celulares.
CO4770950A1 (es) Composicion antiparasitaria para tratamiento y proteccion de animales de compania
PE20070829A1 (es) Inhibidores cetp heterociclicos
HUT42272A (en) Insecticides containing derivatives of nitro-methilen and process for production of the derivatives of nitromethilen
AR019365A1 (es) Compuesto de 1-piperidin-3-fenil-butil-naftamida, proceso para prepararlo, composicion farmaceutica y uso para fabricar un medicamento util para eltratamiento de una enfermedad por antagonistas de taquicininas neuropeptidicas endogenas
MX9702670A (es) Derivado de azol.
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
PE20020759A1 (es) Derivados de bencilamina con base prolina como inhibidores de trombina
DE3866415D1 (de) Mittel zur insekten- und milbenabwehr.
PE20040375A1 (es) Amino-piperidinas 4,4-disustituidas como ligandos de receptores de melanocortina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal